What prompted the recall of Bextra?

Bextra warning statements regarding cardiovascular safety follow the recent Vioxx recall that occurred on September 30, 2004. The recall was prompted by research findings indicating that patients taking Vioxx for eighteen months double their risk of suffering from a serious heart attack or stroke. Because Bextra, like Vioxx, is a COX-2 selective nonsteroidal anti-inflammatory drugs and because it is so similar to Bextra in its actions on the body, warnings were raised regarding the safety of Bextra and all other COX-2 selective NSAIDs.